Sulfamic acid, N-[2-[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester
| Title | Journal |
|---|---|
| Coronary circulatory function in patients with the metabolic syndrome. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110901 |
| The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice. | Journal of neuropathology and experimental neurology 20100801 |
| Acyl-coenzyme A: cholesterol acyltransferase inhibitor Avasimibe affect survival and proliferation of glioma tumor cell lines. | Cancer biology & therapy 20100615 |
| Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20091101 |
| Synthesis and structure-activity relationships of N-(4-amino-2,6-diisopropylphenyl)-N'-(1,4-diarylpiperidine-4-yl)methylureas as anti-hyperlipidemic agents. | Bioorganic & medicinal chemistry 20090701 |
| Novel 1,4-diarylpiperidine-4-methylureas as anti-hyperlipidemic agents: dual effectors on acyl-CoA:cholesterol O-acyltransferase and low-density lipoprotein receptor expression. | Bioorganic & medicinal chemistry letters 20090215 |
| Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes. | Journal of biochemical and molecular toxicology 20090101 |
| Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and biological activities by introduction of carboxylic acid. | Journal of medicinal chemistry 20080814 |
| In silico prediction of pregnane X receptor activators by machine learning approaches. | Molecular pharmacology 20070101 |
| Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis. | Pathophysiology of haemostasis and thrombosis 20070101 |
| Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. | Drug metabolism and disposition: the biological fate of chemicals 20061001 |
| [New agents against atherosclerosis tested. Alarming findings, ACAT inhibitors seem to have proatherogenic effects]. | Lakartidningen 20061001 |
| Effect of atherosclerotic regression on total luminal size of coronary arteries as determined by intravascular ultrasound. | The American journal of cardiology 20060701 |
| The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. | Biochimica et biophysica acta 20051230 |
| Inhibitors of acyl-coenzyme a: cholesterol acyltransferase. | Current drug targets. Cardiovascular & haematological disorders 20051201 |
| Effects of avasimibe on cytochrome P450 2C9 expression in vitro and in vivo. | Drug metabolism and disposition: the biological fate of chemicals 20041201 |
| Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. | Circulation 20041123 |
| Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages. | DNA and cell biology 20040501 |
| Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. | Atherosclerosis 20031201 |
| Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor. | The Journal of pharmacology and experimental therapeutics 20030901 |
| Pharmacology of the ACAT inhibitor avasimibe (CI-1011). | Cardiovascular drug reviews 20030101 |
| Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial. | American heart journal 20021001 |
| Avasimibe and atorvastatin synergistically reduce cholesteryl ester content in THP-1 macrophages. | European journal of pharmacology 20020906 |
| Anti-atherogenic effects of the acyl-CoA:cholesterol acyltransferase inhibitor, avasimibe (CI-1011), in cultured primary human macrophages. | Atherosclerosis 20020301 |
| Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor. | Biochemical pharmacology 20020201 |
| New advances in lipid-modifying therapies for reducing cardiovascular risk. | Cardiology 20020101 |
| A role for smooth endoplasmic reticulum membrane cholesterol ester in determining the intracellular location and regulation of sterol-regulatory-element-binding protein-2. | The Biochemical journal 20010901 |
| Therapies on the horizon for cholesterol reduction. | Clinical cardiology 20010801 |
| The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression. | Atherosclerosis 20010701 |
| Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. | Atherosclerosis 20010701 |
| Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. | Circulation 20010403 |
| Preclinical safety evaluation of avasimibe in beagle dogs: an ACAT inhibitor with minimal adrenal effects. | Toxicological sciences : an official journal of the Society of Toxicology 20010201 |